Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis. Issue 1 (4th June 2022) - Dimopoulos, Meletios A.; Moreau, Philippe; Augustson, Bradley; Castro, Nelson; Pika, Tomas; Delimpasi, Sosana; De la Rubia, Javier; Maiolino, Angelo; Reiman, Tony; Martinez‐Lopez, Joaquin; Martin, Thomas; Mikhael, Joseph; et al.